Medical Devices APAC

APAC Nuclear Medicine Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Nuclear Medicine Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.42 Bn Placeholder estimate
Estimate 2025 $2.69 Bn 18.5% of the global market
Projected 2034 $6.99 Bn 160% Adds $4.30 Bn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 61% of 193 Medical Devices markets here
Key players 6 +1
  • APAC is 18.51% of the global market.
  • Among regions, the largest is North America at $7.20 Bn.
  • Fastest growing: Africa at 11.5% a year.
  • APAC ranks 3rd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$4.30 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Nuclear Medicine Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.42 Bn — —
2025 (base) $2.69 Bn +$270.6 Mn —
2026 (forecast) $2.99 Bn +$300.9 Mn +11.2%
2027 (forecast) $3.32 Bn +$334.7 Mn +23.7%
2028 (forecast) $3.69 Bn +$372.1 Mn +37.5%
2029 (forecast) $4.11 Bn +$413.8 Mn +52.9%
2030 (forecast) $4.57 Bn +$460.2 Mn +70%
2031 (forecast) $5.08 Bn +$511.7 Mn +89.1%
2032 (forecast) $5.65 Bn +$569.0 Mn +110.2%
2033 (forecast) $6.28 Bn +$632.7 Mn +133.8%
2034 (forecast) $6.99 Bn +$703.6 Mn +160%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Nuclear Medicine Market Analysis at a glance
Market size, 2025$2.69 Bn placeholder estimate
Forecast, 2034$6.99 Bn placeholder estimate
Growth (CAGR), 2025–203411.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, application and end user (see all)
Key playersGE Healthcare, Siemens Healthineers, Lantheus Holdings, Cardinal Health, Curium and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Nuclear Medicine Market Analysis Executive Summary

Nuclear medicine uses small amounts of radioactive tracers and special cameras to see how organs work and to treat some cancers.

Key segments of the nuclear medicine market include product (SPECT Systems, PET Systems and Diagnostic Radiotracers) and application (Oncology, Cardiology and Neurology).

Bar chart: Asia Pacific Nuclear Medicine market size, 2024–2034, placeholder estimates. $2.42 Bn in 2024, $2.69 Bn in 2025 and $6.99 Bn in 2034, 11.2% CAGR.
Asia Pacific Nuclear Medicine market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Nuclear Medicine Market Dynamics

Market Growth Drivers

More imaging for cancer and heart disease, older populations and sharper, faster scanners are driving the nuclear medicine market. Clinicians also use imaging earlier in care.

Opportunity

AI-assisted reading, compact systems for clinics and the replacement of old scanners give the nuclear medicine market room to grow.

Market Restraints

High equipment prices, a shortage of trained staff and long replacement cycles in public hospitals hold back the nuclear medicine market.

Competitive Landscape for Nuclear Medicine Market in APAC

The nuclear medicine market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Nuclear Medicine Market in APAC

Nuclear Medicine in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], Ministry of Health (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Ministry of Health (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Ministry of Health of Indonesia. Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Ministry of Health of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how nuclear medicine products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Public data, with sources

Nuclear Medicine in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Nuclear Medicine market in Asia Pacific?
Placeholder estimate: about $2.69 Bn in 2025, rising to about $6.99 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Nuclear Medicine market in Asia Pacific growing?
Placeholder estimate: about 11.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Nuclear Medicine market report cover?
The report splits the market by product (SPECT Systems, PET Systems, Diagnostic Radiotracers, Therapeutic Radiopharmaceuticals), application (Oncology, Cardiology, Neurology, Thyroid Disease) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Nuclear Medicine market?
Key players include GE Healthcare, Siemens Healthineers, Lantheus Holdings, Cardinal Health, Curium and Bracco.
What is driving the Nuclear Medicine market?
More imaging for cancer and heart disease, older populations and sharper, faster scanners are driving the nuclear medicine market. Clinicians also use imaging earlier in care.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on imaging and oncology

See the topic